I agree with you to an extent. There is potentially some benefit to a “right to try” especially in patients with no other options. It’s just the flip side of easier approval is more adverse events and inefficacious drugs.
In general people tend to be angrier about unexpected adverse events than grateful for treatments. The anger around thalidomide for example. Hence the high bars that have been set. “First do no harm”.
If you take the kudos for approving drugs easier and there is likely to be some you also have to take the responsibility for the adverse events you create and expense associated with a higher proportion of ineffective drugs.
maybe the bar is set too high? I’m not sure but that is the conversation. I would suggest any change should be done in a very considered way and there should be appropriate ongoing checks on these easily approved drugs going forward. Hopefully they are having those conversations.
PYC Price at posting:
$1.02 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)